Tag Archives: transactionname

3 ETFs To Buy As Housing Picks Up

Though the U.S. housing market saw a rough first quarter, sales are picking up as the spring selling season gets into full swing. The season usually warms up in March and sees maximum business till the back-to-school season in September. The spring selling season generally brings in improving sales trends. Higher job numbers, a reassuring economy, moderating home price gains, affordable interest/mortgage rates, rising rentals, recent federal initiatives to increase mortgage availability and a limited supply of inventory point to an inevitable pickup in the housing market. Even though the U.S. economy faltered in the first quarter of the year, this can mostly be attributed to the strong dollar and a harsh winter. The economy is expected to improve later this year. Rising consumer confidence, a reassuring economy and improving employment trends should lead to better home sales as the year progresses. Last year saw slowing housing price gains on stabilizing demand. The trend is expected to continue in 2015 as well. Moreover, housing should remain an affordable option in 2015, as mortgage rates are still below historical levels. Even if mortgage rates rise in the latter half of the year – as is widely anticipated – housing will likely remain reasonable. Apartment rental rates have also continued to move up, making home buying more attractive than renting. To add to the positives, plans from the White House to cut premiums on mortgage insurance should increase mortgage availability and thereby encourage home buying among first-time homebuyers. With oil prices continuing their downward journey and the economy largely on the mend, the desire to own new homes should get a shot in the arm. ETFs to Tap the Sector Given the improving fundamentals, the homebuilding sector deserves a closer look. For investors willing to play the space in a less risky way, an ETF approach can be a good idea. This technique can help to spread out assets among a wide variety of companies and reduce company-specific risk at a very low cost. Below, we have highlighted three ETFs that are worth looking into. SPDR Homebuilders ETF (NYSEARCA: XHB ) XHB is one of the more popular homebuilding ETFs in the market today, with assets under management of around $1.58 billion and a trading volume of roughly 4.28 million shares a day. The fund has an expense ratio of 35 basis points. The fund holds 37 stocks in its basket, with 50% of the assets going to mid caps and 6% comprising large-cap stocks. Despite the smaller holding pattern, the fund does not appear to be concentrated in the top 10 holdings. The fund has just 33.9% in the top 10, with Aaron’s Inc. (NYSE: AAN ), A. O. Smith Corporation (NYSE: AOS ) and Tempur Sealy International Inc. (NYSE: TPX ) occupying the top 3 positions with asset allocation of 3.84%, 3.54% and 3.41%, respectively. The fund’s assets include 32.83% homebuilders, 29.27% building products and 15.59% home furnishing retail stocks. The fund carries a Zacks Rank #3 (Hold), with a high level of risk. iShares U.S. Home Construction ETF (NYSEARCA: ITB ) Another popular choice in the homebuilding sector is ITB, which tracks the Dow Jones U.S. Select Home Construction Index. It has $2.03 billion in assets, with a trading volume of roughly 4.1 million shares a day, while its expense ratio is just 45 basis points. The fund holds 37 stocks in its basket, of which only 11% are large cap securities. The fund has a concentrated approach in the top 10 holdings, with 57.7% of its asset base invested in them. Among individual holdings, the top stocks in the ETF include D. R. Horton, Inc. (NYSE: DHI ), Lennar (NYSE: LEN ) and Pulte (NYSE: PHM ), with asset allocation of 10.61%, 10.45% and 8.30%, respectively. Homebuilders accounts for around 65% of this fund. The fund carries a Zacks Rank #3 (Hold), with a high level of risk. PowerShares Dynamic Building & Construction Portfolio ETF (NYSEARCA: PKB ) This ETF comprises around 30 housing companies, and has its assets invested across all classes of the market spectrum. Engineering and construction stocks comprise 21% of the fund, followed by building materials companies that account for 17%. A look at the style pattern reveals that the fund has a preference for growth stocks. The fund manages an asset base of $56.4 million, and has an expense ratio of 63 basis points. The fund has only 15% in large cap securities and 46.3% in the top 10 holdings. The fund carries a Zacks Rank #3 (Hold), with a high level of risk. To Sum Up While the housing market slowed down in the first quarter, homebuilders are increasingly optimistic of the spring selling season. However, increasing competitive pressure and rising land and construction cost amid moderating home price increases are the headwinds in the housing market. Original Post

5 Stocks Leading XBI Biotech ETF Higher

The biotech corner of the health care space is having a stellar run like last year and still remains a favorite investment destination for investors. This is primarily thanks to strong earnings growth, merger & acquisition frenzy, promising drug launches, cost-cutting efforts, a rise in the aging population, insatiable demand for new drugs, ever-increasing health care spending, expansion into emerging markets and the Affordable Care Act or Obamacare. Further, biotech stocks provide a defensive tilt to the portfolio amid political or economic turmoil. While most of the biotech ETFs has given incredible performances so far in the year, the ultra-popular – SPDR S&P Biotech ETF (NYSEARCA: XBI ) – is not far behind. It is the third best performing ETF in the biotech space, returning nearly 39.5%. XBI in Focus With AUM of $2.3 billion and average daily volume of close to a million shares, XBI is extremely liquid and an easily traded fund. It provides equal weight exposure across 106 stocks by tracking the S&P Biotechnology Select Industry Index. This suggests that the product has no concentration issue and offers huge diversification benefits. The product has a definite tilt toward small cap securities, as mid and large caps account for only around 10% each. It charges a relatively low fee of 35 bps a year for the exposure and has a Zacks ETF Rank of 2 or ‘Buy’ rating with a High risk outlook. Several stocks in the ETF portfolio are worth noting, as these have been the real stars and have contributed much to its outstanding performance. Below, we have highlighted those five best performing stocks and each takes nearly 1% share in the fund’s basket, irrespective of its position: Best Performing Stocks of XBI Eagle Pharmaceuticals Inc. (NASDAQ: EGRX ): Based in Woodcliff Lake NJ, this specialty pharmaceutical company is focused on developing and commercializing injectable products, primarily in the critical care and oncology areas in the United States. Having a Zacks Rank of #3 (Hold), the stock surged nearly five-folds in the year-to-date time frame given its incredible growth prospect with a Growth Style Score of ‘A’. The company’s earnings are expected to grow a whopping 137.90% this year compared to industry growth projection of 9.75% and sales growth projection is also robust at 264.47% versus the industry average of 4.43%. The stock also has a solid Zacks Industry Rank in the top 39% at the time of writing. Heron Therapeutics Inc. (NASDAQ: HRTX ): Based in Redwood City, CA, this biotech company develops products using its proprietary Biochronomer polymer-based drug delivery platform to address unmet medical needs. The stock has delivered incredible returns of over 215% so far in the year and is still showing solid momentum with a Momentum Style Score of ‘A’. The stock has seen narrowing loss estimate from $2.78 per share to $2.56 per share over the past 60 days, suggesting some upside. This represents earnings growth of 10.9% year-over year, up from the industry average of 1.5% growth. HRTX has a Zacks Rank #3 and a solid Zacks Industry Rank in the top 41%. Exelixis Inc. (NASDAQ: EXEL ): The stock was recently upgraded by a notch to Zacks Rank #2 (Buy), and has climbed nearly 180% so far this year. Based in South San Francisco, the company develops and sells small molecule therapies for the treatment of cancer in the United States. Though the company’s earnings are expected to grow 42.79% year over year this year, well above the industry average of 6.43%, earnings yield is highly negative at 20.31% and worse than the industry average of 7.84%. As such, the stock currently does not pose ideal flavors of growth, value and momentum. However, it falls in a strong industry category, having a Zacks Rank in the top 42%. Retrophin Inc. (NASDAQ: RTRX ): Based in San Diego, CA, this biopharma company focuses on the development, acquisition and commercialization of drugs for the treatment of serious, catastrophic or rare diseases for which there are currently no viable options for patients. The stock, with an industry Zacks Rank in the top 42%, has gained 177% in the year-to-date time frame. Though the company’s earnings and revenues are expected to grow more than the industry average this year, its growth and value prospects are gloomy with a Growth Style Score of ‘D’ and Value Style Score of ‘F’. This is because the stock has a Zacks Rank #4 (Sell) and seen massive negative estimate revisions from a loss of 96 cents per share to a loss of $1.64 per share for the current fiscal year. This suggests some pain for this company in the coming weeks. Prothena Corp Plc (NASDAQ: PRTA ): The stock has delivered robust returns of 159% so far this year but the trend of outperformance is likely to snap in the coming weeks. This is especially true as this Zacks Rank #3 stock also has a dull Growth and Value Style score of ‘F’ each despite the strong industry Zacks Rank in the top 42%. Earnings and revenues are expected to decline 796.5% and 95.3%, respectively, for this year. Based in Dublin, Ireland, Prothena is a late-stage clinical biotechnology company focused on the discovery, development, and commercialization of protein immunotherapy programs for the treatment of diseases that involve amyloid or cell adhesion. Original Post

Selling At The Best And Worst Possible Times

In a previous article, I expanded on Peter Lynch’s “high and low analysis.” That view looked at potential returns had you bought at the high and low price each and every year. This commentary takes the opposite view: seeing what happens if you sold at the high and low price each and every year. In a previous article , I expanded upon Peter Lynch’s “high and low” analysis. This involves looking at what would have happened if you invested at the very best and worst times (the high and low price, respectively) each and every year. The process was simple, but the takeaway is enormously instructive: “Investing at the high or low, especially over the long term, is not the difference between positive and negative returns. The difference between perfect timing and miserable timing over lengthy time periods is perhaps a couple of percent. Once you figure this out, it becomes clear that you should be focusing on the amount you can contribute and utilizing a long time frame, rather than concerning yourself with unknowable short-term fluctuations.” In Lynch’s example, the difference between perfect yearly purchases and dreadful annual timing was about 1% per annum. In my example, the difference was slightly larger, but the basic conclusion remained intact: “it’s not about timing the market, it’s about time in the market.” These demonstrations were based on the purchase side: “what happens if I bought each and every year?” For this article, I wanted to focus on the selling side. To make the process simple, we can rely on the same high and low price information as generated by the SPDR S&P 500 Trust ETF (NYSEARCA: SPY ). Here’s a look at the low price from each year dating back to 1996: Year Low Date Price 1996 1/10/96 $59.97 1997 4/11/97 $73.38 1998 1/9/98 $92.31 1999 1/14/99 $121.22 2000 12/20/00 $126.25 2001 9/21/01 $97.28 2002 10/9/02 $78.10 2003 3/11/03 $80.52 2004 8/6/04 $106.85 2005 4/20/05 $113.80 2006 6/13/06 $122.55 2007 3/5/07 $137.35 2008 11/20/08 $75.45 2009 3/9/09 $68.11 2010 7/2/10 $102.20 2011 10/3/11 $109.93 2012 1/3/12 $127.50 2013 1/3/13 $145.73 2014 2/3/14 $174.17 Additionally, we have the high price available as well from the same article: Year High Date Price 1996 11/25/96 $76.13 1997 12/5/97 $98.94 1998 12/29/98 $124.31 1999 12/29/99 $146.81 2000 3/24/00 $153.56 2001 2/1/01 $137.93 2002 1/4/02 $117.62 2003 12/31/03 $111.28 2004 12/29/04 $121.36 2005 12/14/05 $127.81 2006 12/14/06 $143.12 2007 10/9/07 $156.48 2008 1/2/08 $144.93 2009 12/28/09 $112.72 2010 12/29/10 $125.92 2011 4/29/11 $136.43 2012 9/14/12 $147.24 2013 12/31/13 $184.69 2014 12/29/14 $208.72 Let’s imagine that you want to supplement your dividend income , such that you take all of the dividends and also begin selling some shares along the way. Now, assuredly it is the goal of a great deal of people to never have to sell a share. However, that doesn’t mean that everyone must follow this route. Nor does it mean that we can’t think about the process. For illustration, let’s imagine that you have a portfolio balance of $1,000,000 back in 1996 (the number isn’t important, just the underlying math). Your idea is to buy shares in an assortment of holdings (in this case an index fund), collect the dividend payments and supplement this by selling an amount of shares each year. Let’s imagine that you want to sell $25,000 worth of shares beginning in 1997, followed by a 2% larger amount in the subsequent years. Here’s what your sold shares would need to amount to through the years: Year Sold Shares 1997 $25,000 1998 $25,500 1999 $26,010 2000 $26,530 2001 $27,061 2002 $27,602 2003 $28,154 2004 $28,717 2005 $29,291 2006 $29,877 2007 $30,475 2008 $31,084 2009 $31,706 2010 $32,340 2011 $32,987 2012 $33,647 2013 $34,320 2014 $35,006 Note that I’m taking a bit of a shortcut here. In reality, instead of focusing solely on the amount of shares you want to sell each year, you’d like to focus both on dividends received and the amount of shares needed to sell in a given year depending on your income requirement. However, with the high and low prices varying dramatically in dates, it’s a rather manual process to figure out the dividends received. It’s not uniform such that sometimes you have more than a year between the high or low price in two consecutive years and sometimes the time frame is just a few months. However, for our purposes, the illustration of selling a certain dollar amount of shares each year will work nicely. Let’s begin by seeing what happens in a “best case” scenario. The low price in 1996 was just under $60 per share. If you bought at this time, you would have been able to purchase 16,675 total shares. Additionally, your expected annual dividend income would have been about $21,000. We can now move on to the process of selling. In 1996, you were able to purchase shares at the best possible time. Let’s presume that you’re also able to sell shares at the best possible time – the highest price of every single year. In 1997, the highest share price was just under $99. In order to generate $25,000 in additional income, you would need to sell roughly 253 shares. As a result, your share count would go down to 16,422 or thereabouts. And so the process continues; in 1998, the highest share price was just over $124. In order to generate $25,500 in supplemental income, you would need to sell 205 shares, bringing your total share count down to 16,217. Here’s a look at your year-end share count from 1996 through 2014 if you kept selling at the high each year: Year Shares 1996 16,675 1997 16,422 1998 16,217 1999 16,040 2000 15,867 2001 15,671 2002 15,436 2003 15,183 2004 14,947 2005 14,718 2006 14,509 2007 14,314 2008 14,100 2009 13,818 2010 13,561 2011 13,320 2012 13,091 2013 12,905 2014 12,738 At first glance, this looks like pretty bad news. You started with 16,675 shares, and nearly two decades later, you’ve sold almost 4,000 shares, bringing your total share count down to “just” 12,700. Yet, it’s important to remain cognizant of what this indicates. Your share count has been reduced, that much is obvious. What’s not as apparent is the idea that you would actually be getting richer over time. Your $1 million beginning portfolio balance would now be worth nearly $2.7 million. Further, in the last 12 months, this amount of shares still would have generated $50,000 worth of dividend payments. Contrary to what many suppose, selling shares doesn’t have to be an exhaustive process to zero. I’m not necessarily personally advocating for this method, but it’s instructive to know that this option exists nonetheless. In this particular case, you would have collected hundreds of thousands in dividends, sold over half a million in shares through the years and still ended up much richer. Of course, this was also a best-case scenario – buying at the low and selling at the high every single year. Let’s take a look at the “worst case”: buying at the high and selling at the low every single year. In 1996, shares of the index traded as high as $76. Had you purchased shares at this price, you would have begun with 13,135 total shares – noticeably lower than the “best” case of buying at the low. Additionally, your expected annual dividend income would be about $17,000. (We could adjust for this in the example, but the illustration is the important part). In 1997, the low share price reached about $73. In turn, in order to reach your $25,000 supplemental income goal, you would need to sell about 341 shares. This would bring your total share count down to fewer than 12,800 (basically where the other example ended). Wash, rinse, and repeat. Here’s a look at your year-end share count each year after selling shares to reach your additional income goals: Year Shares 1996 13,135 1997 12,795 1998 12,518 1999 12,304 2000 12,094 2001 11,816 2002 11,462 2003 11,113 2004 10,844 2005 10,586 2006 10,343 2007 10,121 2008 9,709 2009 9,243 2010 8,927 2011 8,627 2012 8,363 2013 8,127 2014 7,926 Once more it’s obvious that your share count will be reduced each and every year. Moreover, it’s also apparent that this situation is markedly worse than the “best case” scenario. Yet, the output provided here is perhaps even more instructive. You began with a $1 million balance that was purchased at the worst possible price point. Then you went on to make sale after sale at the worst possible time each and every year. However, those 7,900 shares would now be worth almost $1.7 million. Further, over the last 12 months, these shares would have provided over $31,000 in dividend income. Expressed differently, even if you bought and sold at the worst possible moments, you would still get richer over time (with a larger cash flow to boot). The reason this works is due to “selling in moderation.” Obviously, you can’t go out and sell 15% of your portfolio each and every year and expect to end up with a higher portfolio balance over time. However, when done purposefully, selling shares and getting richer do not have to be opposite notions. The thing of it all is that you’re not going to complete either exercise. You’re not going to have perfect timing and you’re not going to have the worst possible timing year-in and year-out. Mathematically it just won’t occur. Yet, even if you did, at least in this illustration, it has been no great tragedy. Regardless of the situation you still ended up with a higher balance. Much like the previous example of consistently buying, it seems that having an underlying plan – rather than figuring out the “best” timing – is a much more important factor. Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. (More…) I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.